- Participation in another study with an experimental drug, where the last administration of the previous IMP was within 8 weeks (or within 5 elimination half-lives for chemical entities or 2 elimination half-lives for antibodies or insulin), whichever is the longer, before administration of IMP in this study, at the discretion of the investigator.